NCT01015521撤回2 期
A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 50
- 主要终点
- Clinical Benefit Response
研究概览
简要总结
This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative and ER+ breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ER+ or TN Breast Cancer
- •Progression on an aromatase inhibitor if ER+
- •Prior treatment with taxane if TN
- •18 years or older
- •Adequate organ function
- •Measurable lesion
排除标准
- •symptomatic pulmonary disease
- •brain metastases
- •pregnant females
研究组 & 干预措施
Aminoflavone Prodrug
Experimental
Aminoflavone to treat ER positive breast cancer patients
干预措施: Aminoflavone Prodrug (Drug)
Aminoflavone Prodrug with pretreatment
Experimental
Aminoflavone Prodrug to treat Triple Negative Breast Cancer
干预措施: Aminoflavone Prodrug (Drug)
结局指标
主要结局
Clinical Benefit Response
时间窗: 6 months
次要结局
- Progression Free Survival(6 monhts)
研究者
相似试验
终止
1 期
AFP464 in Treating Patients With Advanced Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificNCT00369200National Cancer Institute (NCI)60
进行中（未招募）
2 期
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate CancerNCT02807805Mamta Parikh37
已完成
2 期
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast CancerBreast CancerNCT02593227Marker Therapeutics, Inc.80
已完成
1 期
Phase 1/2 Trial of AEF0217 in Participants With Down SyndromeDown SyndromeNCT05748405Aelis Farma40
已完成
2 期
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) GeneCarcinoma, Non-Small-Cell LungNCT00932451Pfizer1,069